Quince Therapeutics
QNCX
126 hedge funds and large institutions have $1.76B invested in Quince Therapeutics in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 27 reducing their positions, and 7 closing their positions.
386% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
79% more capital invested
Capital invested by funds: $982M → $1.76B (+$777M)
63% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 27
26% more funds holding
Funds holding: 100 → 126 (+26)
23% more call options, than puts
Call options by funds: $133M | Put options by funds: $108M
0.01% more ownership
Funds ownership: 0.31% → 0.32% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$19M |
| 2 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$14.9M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$12.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.68M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$7.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SUT
SC US (TTGP)
Menlo Park,
California
|
-$29.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.69M |
| 3 |
JG
Jefferies Group
New York
|
-$2.77M |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$2.66M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.32M |
QNCX Hedge Fund Activity: Q3 2021 in Review
126 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q3 2021, worth a combined $1.76B — up 79% from $982M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new QNCX positions and 7 closed out — a net gain of 27 holders — while 44 added to existing stakes and 27 trimmed.
The largest buyer was Capital International Investors, adding an estimated $19M. The largest seller was SC US (TTGP), exiting entirely with an estimated $29.7M sold.
- 126 institutional investors held Quince Therapeutics (QNCX) as of Q3 2021, up from 100 in Q2 2021.
- Funds reported $1.76B of Quince Therapeutics stock for Q3 2021, up 79% quarter-over-quarter.
- 34 funds opened new Quince Therapeutics positions in Q3 2021 and 7 closed out, a net change of +27 holders.
- The largest Quince Therapeutics buyer in Q3 2021 was Capital International Investors, an estimated $19M added.
- The largest Quince Therapeutics seller in Q3 2021 was SC US (TTGP), an estimated $29.7M sold.
Based on aggregated 13F filings for Q3 2021.